BDSX

Biodesix, Inc. (BDSX) | Rumor.io

Biodesix

BDSX

Attention (50-day avg)0%

Attention rank (50-day avg)#2,147

Bullish sentiment (50-day avg)100%

Price to earnings ratio-6.49

Market capitalization321M

Earnings per share-3.1

Dividend yield (TTM)—

Revenue (annual)88.5M

Net income (annual)-35.3M

Social

What share of all stock conversation is about BDSX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Feb 26

Biodesix, Inc. ($BDSX) reported Q4 2025 results, with revenue of $28.8M and gross margin of 83%.
The company achieved its first-ever positive Adjusted EBITDA of $0.5M and provided 2026 guidance of $106-112M in revenue.
Biodesix anticipates 23% growth in 2026, with continued improvement towards sustained Adjusted EBITDA positivity and gross margin maintained at approximately 80%.

Generated by AI

Sentiment

Of the messages about BDSX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	83.01% -4.36
Bearish	—	—	0% 0	16.99% +4.36

Bullish· Jan 21

Biodesix, Inc. ($BDSX) has broken through a key resistance level at $9.89, with a surge in volume confirming the technical breakout.
The stock's rebound of 26% in the short term has analysts projecting upside potential as high as 325%, with a potential price target of $25-$35 by 2026.
A potential acquisition by Thermo Fisher Scientific could make strategic sense, expanding into adjacent diagnostics and biopharma support, which could strengthen the company's core business and broaden long-term growth.

Bearish· Jan 12

$BDSX has a history of volatile price movements, with the author experiencing significant losses due to sudden drops.
The company's liquidity and financial situation are concerns, with the author speculating that Biodesix, Inc. may need to issue an offering to stay afloat.
$BDSX's trading style is seen as "trappy" and prone to false breakouts, with the author expecting the stock to continue falling after a sharp spike.

Generated by AI

Topics

Of the messages about BDSX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	0%	92.86%	42.21%
Technical Analysis	—	100%	7.14%	28.52%
Analysts	—	0%	0%	21.2%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	3.75%
Macro	—	0%	0%	4.32%

Announcements· Feb 2

Biodesix, Inc. (BDSX) has exposure at LINK, a platform that allows it to engage with enterprise buyers focused on long-term operational efficiency.
LINK 2026 has put Biodesix, Inc. (BDSX) in front of leaders running $100M+ logistics budgets, with one follow-up from that room potentially outweighing years of retail chatter.
Biodesix, Inc. (BDSX) has strengthened its alignment with enterprise buyers through RIME exposure at LINK, which attracts leaders overseeing 7–9 digit P&Ls.

Technical Analysis· Jan 12

$BDSX is showing strong relative strength versus the market, holding gains while others chop, and this is a bullish sign.
$BDSX is waking up now after holding support, with price pushing higher with steady demand and momentum traders paying attention.
$BDSX is in a strong trend, with buyers stepping in with conviction and price responding quickly to demand, with targets including the 200 ema.

Generated by AI

Community

Of the messages about BDSX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	1.12%	19.24%
Newcomers	—	100%	98.88%	80.76%

Regulars· Jan 12

Biodesix, Inc.'s Q4 revenue of $28.8M and FY2025 revenue of $88.5M represent a 41% and 24% increase over the respective prior year comparable periods.
The company's strong relative strength versus the market is a bullish sign, as it continues to hold gains while others chop.
A premarket surge of +39% in Biodesix, Inc.'s stock may be driven by a recent PR/filing, and investors should confirm the source before making a trade.

Newcomers· Feb 26

Newcomers are focused on Biodesix's (BDSX) profitability, with some noting the company achieved its first positive Adjusted EBITDA in Q4 2025.
Concerns are raised about RIME, a company that has a similar business profile to Biodesix, citing SEC investigations, lack of audited financials, and claims of fake press releases about contracts with major companies.
Critics of RIME argue that it is a high-risk investment, with a history of zero earnings, toxic debt, and constant dilution, comparing it to a lottery with a losing ticket.

Generated by AI

News

Biodesix Expands MRD Testing With Tumor-Informed and Tumor-Naive Tests

BDSX advances two blood-based MRD programs with Bio-Rad and Thermo Fisher to broaden access to cancer monitoring.

1d agoYahoo Finance

Biodesix Advances MRD Monitoring Programs With Bio-Rad and Thermo Fisher

Biodesix, Inc. (NASDAQ:BDSX) reported progress in two collaborative Molecular Residual Disease (MRD) monitoring programs designed to detect circulating tumor DNA (ctDNA) in blood following cancer treatment.

6d agoYahoo Finance

Biodesix advances MRD testing programs with Bio-Rad, Thermo Fisher

6d agoInvesting.com

Biodesix (BDSX) Stock Gets Fair Value Boost On Revenue And Margin Optimism

Biodesix has seen its fair value estimate move from US$30.83 to US$34.00, which works out to roughly a 10% uplift in the price target range used by analysts. Recent research coverage links this shift to a mix of optimism around revenue momentum and margin potential, along with some caution about execution and the timing of profitability. As you read on, you will see how these moving parts shape the current analyst narrative and what to watch as it evolves from here. Stay updated as the Fair...

11d agoYahoo Finance

Biodesix: Growing Fast While Trading Below Many Diagnostics Peers (NASDAQ:BDSX)

20d agoSeeking Alpha

What Makes Biodesix, Inc. (BDSX) a Strong Momentum Stock: Buy Now?

Does Biodesix, Inc. (BDSX) have what it takes to be a top stock pick for momentum investors? Let's find out.

29d agoYahoo Finance

Also Discussed

Investors talking about BDSX also mention

#	Name	Attention
1	Lulu's Fashion Lounge Holdings, Inc.LVLU	0%0
2	Atara Biotherapeutics, Inc.ATRA	0%0
3	Intelligent Bio Solutions Inc.INBS	0%0
4	IN8bio, Inc.INAB	0%0
5	CFSB - CFSB Bancorp, Inc.	——
6	Maison Solutions Inc. Class A Common StockMSS	0%new
7	Falcon's Beyond Global, Inc. Class A Common StockFBYD	0%new
8	Acrivon Therapeutics, Inc.ACRV	0%new
9	Envirotech Vehicles Inc.EVTV	0%0
10	Caesarstone Ltd.CSTE	0%0

Biodesix, Inc.

Healthcare
Diagnostics & Research

Biodesix, Inc. is a diagnostic solutions company focused on blood-based testing and development services for lung disease, with a strong emphasis on lung cancer care. Biodesix provides commercial tests such as Nodify XL2 and Nodify CDT for lung nodule risk assessment, along with GeneStrat ddPCR, GeneStrat NGS, and VeriStrat to support diagnostic and treatment decisions in oncology. The company also serves biopharmaceutical, life sciences, and diagnostic partners with services that include biomarker discovery, assay design, clinical trial sample testing, regulatory support, reimbursement support, commercialization, and logistics. By combining laboratory diagnostics with research and development capabilities, Biodesix plays a specialized role in precision medicine and respiratory health, helping clinicians and industry customers address unmet needs in lung-related disease management.

Website

Location

919 West Dillon Road

Louisville, CO, 80027

United States

Social

What share of all stock conversation is about BDSX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Feb 26

Biodesix, Inc. ($BDSX) reported Q4 2025 results, with revenue of $28.8M and gross margin of 83%.
The company achieved its first-ever positive Adjusted EBITDA of $0.5M and provided 2026 guidance of $106-112M in revenue.
Biodesix anticipates 23% growth in 2026, with continued improvement towards sustained Adjusted EBITDA positivity and gross margin maintained at approximately 80%.

Generated by AI

Sentiment

Of the messages about BDSX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	83.01% -4.36
Bearish	—	—	0% 0	16.99% +4.36

Bullish· Jan 21

Biodesix, Inc. ($BDSX) has broken through a key resistance level at $9.89, with a surge in volume confirming the technical breakout.
The stock's rebound of 26% in the short term has analysts projecting upside potential as high as 325%, with a potential price target of $25-$35 by 2026.
A potential acquisition by Thermo Fisher Scientific could make strategic sense, expanding into adjacent diagnostics and biopharma support, which could strengthen the company's core business and broaden long-term growth.

Bearish· Jan 12

$BDSX has a history of volatile price movements, with the author experiencing significant losses due to sudden drops.
The company's liquidity and financial situation are concerns, with the author speculating that Biodesix, Inc. may need to issue an offering to stay afloat.
$BDSX's trading style is seen as "trappy" and prone to false breakouts, with the author expecting the stock to continue falling after a sharp spike.

Generated by AI

Topics

Of the messages about BDSX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	0%	92.86%	42.21%
Technical Analysis	—	100%	7.14%	28.52%
Analysts	—	0%	0%	21.2%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	3.75%
Macro	—	0%	0%	4.32%

Announcements· Feb 2

Biodesix, Inc. (BDSX) has exposure at LINK, a platform that allows it to engage with enterprise buyers focused on long-term operational efficiency.
LINK 2026 has put Biodesix, Inc. (BDSX) in front of leaders running $100M+ logistics budgets, with one follow-up from that room potentially outweighing years of retail chatter.
Biodesix, Inc. (BDSX) has strengthened its alignment with enterprise buyers through RIME exposure at LINK, which attracts leaders overseeing 7–9 digit P&Ls.

Technical Analysis· Jan 12

$BDSX is showing strong relative strength versus the market, holding gains while others chop, and this is a bullish sign.
$BDSX is waking up now after holding support, with price pushing higher with steady demand and momentum traders paying attention.
$BDSX is in a strong trend, with buyers stepping in with conviction and price responding quickly to demand, with targets including the 200 ema.

Generated by AI

Community

Of the messages about BDSX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	1.12%	19.24%
Newcomers	—	100%	98.88%	80.76%

Regulars· Jan 12

Biodesix, Inc.'s Q4 revenue of $28.8M and FY2025 revenue of $88.5M represent a 41% and 24% increase over the respective prior year comparable periods.
The company's strong relative strength versus the market is a bullish sign, as it continues to hold gains while others chop.
A premarket surge of +39% in Biodesix, Inc.'s stock may be driven by a recent PR/filing, and investors should confirm the source before making a trade.

Newcomers· Feb 26

Newcomers are focused on Biodesix's (BDSX) profitability, with some noting the company achieved its first positive Adjusted EBITDA in Q4 2025.
Concerns are raised about RIME, a company that has a similar business profile to Biodesix, citing SEC investigations, lack of audited financials, and claims of fake press releases about contracts with major companies.
Critics of RIME argue that it is a high-risk investment, with a history of zero earnings, toxic debt, and constant dilution, comparing it to a lottery with a losing ticket.

Generated by AI

Biodesix

Social

Feb 26

Bullish· Jan 21

Bearish· Jan 12

Announcements· Feb 2

Technical Analysis· Jan 12

Regulars· Jan 12

Newcomers· Feb 26

Biodesix Expands MRD Testing With Tumor-Informed and Tumor-Naive Tests

Biodesix Advances MRD Monitoring Programs With Bio-Rad and Thermo Fisher

Biodesix advances MRD testing programs with Bio-Rad, Thermo Fisher

Biodesix (BDSX) Stock Gets Fair Value Boost On Revenue And Margin Optimism

Biodesix: Growing Fast While Trading Below Many Diagnostics Peers (NASDAQ:BDSX)

What Makes Biodesix, Inc. (BDSX) a Strong Momentum Stock: Buy Now?

Also Discussed

Biodesix, Inc.

Company Information

Location

Biodesix Expands MRD Testing With Tumor-Informed and Tumor-Naive Tests

Biodesix Advances MRD Monitoring Programs With Bio-Rad and Thermo Fisher

Biodesix advances MRD testing programs with Bio-Rad, Thermo Fisher

Biodesix (BDSX) Stock Gets Fair Value Boost On Revenue And Margin Optimism

Biodesix: Growing Fast While Trading Below Many Diagnostics Peers (NASDAQ:BDSX)

What Makes Biodesix, Inc. (BDSX) a Strong Momentum Stock: Buy Now?

Also Discussed

Social

Feb 26

Bullish· Jan 21

Bearish· Jan 12

Announcements· Feb 2

Technical Analysis· Jan 12

Regulars· Jan 12

Newcomers· Feb 26